188 related articles for article (PubMed ID: 35589075)
1. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Arnould L; Viola F; Zarranz-Ventura J; Barthelmes D; Creuzot-Garcher C; Gillies M;
Ophthalmol Retina; 2022 Nov; 6(11):1044-1053. PubMed ID: 35589075
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project.
Shah J; Nguyen V; Hunt A; Mehta H; Romero-Nuñez B; Zarranz-Ventura J; Viola F; Bougamha W; Barnes R; Barthelmes D; Gillies MC; Fraser-Bell S
Ophthalmol Retina; 2022 Jul; 6(7):540-547. PubMed ID: 35307607
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry.
Gabrielle PH; Maitrias S; Nguyen V; Arnold JJ; Squirrell D; Arnould L; Sanchez-Monroy J; Viola F; O'Toole L; Barthelmes D; Creuzot-Garcher C; Gillies M;
Acta Ophthalmol; 2022 Dec; 100(8):e1569-e1578. PubMed ID: 35322568
[TBL] [Abstract][Full Text] [Related]
5. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
Storey PP; Pancholy M; Wibbelsman TD; Obeid A; Su D; Borkar D; Garg S; Gupta O
Ophthalmology; 2019 Oct; 126(10):1424-1431. PubMed ID: 31042567
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration.
Mammo DA; Ringeisen AL; Parke DW
Ophthalmol Retina; 2020 Oct; 4(10):973-978. PubMed ID: 32651157
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
9. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Wolff B; Essex R; Young S; Hunt A; Gemmy Cheung CM; Arnold JJ; Barthelmes D; Creuzot-Garcher C; Gillies M;
Ophthalmol Retina; 2020 Sep; 4(9):861-870. PubMed ID: 32574830
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and surgical outcomes of rhegmatogenous retinal detachments that develop after intravitreal injections.
Baba T; Miura G; Tatsumi T; Sakurai M; Yamamoto S
Jpn J Ophthalmol; 2021 Jul; 65(4):492-496. PubMed ID: 33745092
[TBL] [Abstract][Full Text] [Related]
11. Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.
Hunt A; Nguyen V; Bhandari S; Ponsioen T; McAllister IL; Arnold J; Young S; Gabrielle PH; Mehta H; O' Toole L; Alforja S; Zarranz-Ventura J; Barthelmes D; Gillies M
Ophthalmol Retina; 2023 Apr; 7(4):338-345. PubMed ID: 36371040
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
13. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
14. Rhegmatogenous Retinal Detachment after Intravitreal Injection.
Brown KR; Yannuzzi NA; Smiddy WE; Gregori NZ; Berrocal AM; Haddock LJ; Schwartz SG; Lee WH; Sridhar J; Wu DM; Flynn HW; Townsend JH
Ophthalmol Retina; 2021 Feb; 5(2):178-183. PubMed ID: 32673672
[TBL] [Abstract][Full Text] [Related]
15. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry.
Boudousq C; Nguyen V; Hunt A; Gillies M; Zarranz-Ventura J; O'Toole L; Mangelschots E; Kusenda P; Schmidt-Erfurdt U; Pollreisz A; Kheir WJ; Arruabarrena C; Vujosevic S; Barthelmes D; Creuzot-Garcher C; Gabrielle PH
Ophthalmol Retina; 2024 Jun; 8(6):527-536. PubMed ID: 38185453
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Squirrell D; Nguyen V; Wang N; Wells JM; Tan T; Barnes R; Barry R; Barthelmes D; Gillies M
Eye (Lond); 2022 Mar; 36(3):594-602. PubMed ID: 33767407
[TBL] [Abstract][Full Text] [Related]
18. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.
Emami-Naeini P; Garmo V; Boucher N; Fernando R; Menezes A
Ophthalmol Retina; 2024 Apr; 8(4):388-398. PubMed ID: 37866681
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
